We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current TARS market cap is 1.1B. The company's latest EPS is USD -3.9713 and P/E is -8.09.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10M | 2.5M | 0 | 1.87M | 13.08M |
| Operating Income | -15.06M | -24.95M | -32.82M | -40.94M | -44.45M |
| Net Income | -13.6M | -23.42M | -31.42M | -39.15M | -41.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 57.03M | 25.82M | 17.45M |
| Operating Income | -4.3M | -27M | -12.16M | -62.71M | -143.16M |
| Net Income | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 227.86M | 211.21M | 188.93M | 268.33M | 265.49M |
| Total Liabilities | 34.96M | 37.81M | 41.2M | 54.67M | 68.5M |
| Total Equity | 192.9M | 173.4M | 147.73M | 213.66M | 196.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 58.32M | 171.97M | 178.91M | 227.86M | 265.49M |
| Total Liabilities | 919k | 5.99M | 12.18M | 34.96M | 68.5M |
| Total Equity | -6.01M | 165.98M | 166.73M | 192.9M | 196.99M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -49.03M | -21.97M | -45.8M | -78.16M | -117.49M |
| Investing | -144.63M | 11.29M | 75.39M | 122.75M | 140.6M |
| Financing | 93.99M | 5.01M | 5.52M | 110.42M | 130.18M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -3.67M | -21.14M | 3.75M | -49.03M | -117.49M |
| Investing | -175k | -456k | -586k | -144.63M | 140.6M |
| Financing | 59.45M | 131.77M | 21k | 93.99M | 130.18M |
| Market Cap | 1.1B |
| Price to Earnings Ratio | -8.09 |
| Price to Sales Ratio | 63.03 |
| Price to Cash Ratio | 4.89 |
| Price to Book Ratio | 5.58 |
| Dividend Yield | - |
| Shares Outstanding | 34.22M |
| Average Volume (1 week) | 567.01k |
| Average Volume (1 Month) | 467.27k |
| 52 Week Change | 72.19% |
| 52 Week High | 42.50 |
| 52 Week Low | 12.57 |
| Spread (Intraday) | 3.96 (11.66%) |
| Company Name | Tarsus Pharmaceuticals Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.tarsusrx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
